Hypersensitivity to flupentixol or melitracen or to any of the excipients of Deanxit.
Circulatory collapse, depressed level of consciousness due to any cause (eg, intoxication with alcohol, barbiturates or opiates), coma, blood disorders, phaeochromocytoma.
Recent myocardial infarction. Any degree of atrioventricular block or disorders of cardiac rhythm and coronary artery insufficiency.
Concomitant treatment with monoamine oxidase inhibitors (MAOIs) is contraindicated (see Interactions). Simultaneous administration of melitracen and MAOIs may cause serotonin syndrome (a combination of symptoms, possibly including agitation, confusion, tremor, myoclonus and hyperthermia).
As with other tricyclic antidepressants, melitracen should not be given to patients receiving MAOIs. Treatment with Deanxit may be instituted 14 days after discontinuation of nonselective MAOIs and minimum 1 day after discontinuation of moclobemide and selegiline. Treatment with MAOIs may be introduced 14 days after discontinuation of Deanxit.